A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study…

Overview of attention for article published in BMC Cancer, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,026 followers.

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol https://t.co/ylOdlekNEW

06 Nov 2022

Reply Repost Favourite

06 Nov 2022

Reply Repost Favourite

New article: A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol https://t.co/7Jtb24WRn4 #lungcancer #o

05 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.